Invasive fungal infections following liver transplantation: Incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007)

2012 ◽  
Vol 18 (9) ◽  
pp. 1100-1109 ◽  
Author(s):  
Anupama Raghuram ◽  
Alejandro Restrepo ◽  
Saman Safadjou ◽  
Jennifer Cooley ◽  
Mark Orloff ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Candida Parapsilosis ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Incidence Risk ◽  
Fluconazole Resistant

Invasive fungal infections following liver transplantation – risk factors, incidence and outcome

2011 ◽  
Vol 16 (3) ◽  
pp. 14-16 ◽  
Author(s):  
Marek J. Pacholczyk ◽  
Beata Lagiewska ◽  
Wojciech Lisik ◽  
Dariusz Wasiak ◽  
Andrzej Chmura
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Fungal Infections ◽  
Invasive Fungal Infections

Epidemiology of invasive fungal infections after liver transplantation and the risk factors of late-onset invasive aspergillosis

2016 ◽  
Vol 22 (2) ◽  
pp. 84-89 ◽  
Author(s):  
Miki Nagao ◽  
Yasuhiro Fujimoto ◽  
Masaki Yamamoto ◽  
Yasufumi Matsumura ◽  
Toshimi Kaido ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Invasive Aspergillosis ◽  
Late Onset ◽  
Fungal Infections ◽  
Invasive Fungal Infections

Risk Factors For Invasive Fungal Infections Complicating Orthotopic Liver Transplantation

1994 ◽  
Vol 170 (3) ◽  
pp. 644-652 ◽  
Author(s):  
L. A. Collins ◽  
M. H. Samore ◽  
M. S. Roberts ◽  
R. Luzzati ◽  
R. L. Jenkins ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
Orthotopic Liver Transplantation ◽  
Fungal Infections ◽  
Invasive Fungal Infections

Invasive fungal infections in pediatric heart transplant recipients: Incidence, risk factors, and outcomes

2010 ◽  
Vol 15 (5) ◽  
pp. 465-469 ◽  
Author(s):  
Theoklis E. Zaoutis ◽  
Steven Webber ◽  
David C. Naftel ◽  
Mary Anne Chrisant ◽  
Beth Kaufman ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Transplant ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Transplant Recipients ◽  
Incidence Risk ◽  
Heart Transplant Recipients ◽  
Pediatric Heart Transplant

scholarly journals 1095. Investigation of Risk Factors Associated with Serious Bacterial, Viral and Invasive Fungal Infections in Hematologic Patients on Ibrutinib

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S576-S577
Author(s):  
Thomas Holowka ◽  
Harry Cheung ◽  
Maricar F Malinis ◽  
Sarah Perreault ◽  
Iris Isufi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Fungal Infections ◽  
Antimicrobial Prophylaxis ◽  
Hematologic Malignancy ◽  
Invasive Fungal Infections ◽  
Risk Of Infection ◽  
Factors Associated ◽  
Serious Infection ◽  
Increased Risk ◽  
Serious Infections

Abstract Background Ibrutinib is a tyrosine kinase inhibitor used to treat hematologic malignancies that may increase the risk of serious infection including invasive fungal infections (IFI). In a study of 378 patients with hematologic malignancy on ibrutinib, serious infection and IFI occurred in 11% and 4% respectively (Varughese et al. Clin Infect Dis). The primary aims of our study were to determine the incidence of serious infection and associated risk factors in patients on ibrutinib. Methods We performed a retrospective analysis of patients with hematologic malignancy prescribed ibrutinib for ≥ 1 week at Yale New Haven Hospital from 2014 to 2019 to identify serious infections defined as those requiring inpatient management. We collected demographic, clinical and oncologic data. Chi-squared tests were used to determine factors associated with an increased risk of infection. Results A total of 254 patients received ibrutinib including 156 with CLL, 89 with NHL and 9 with other leukemias. Among these, 21 underwent HSCT, 9 complicated by GVHD. There were 51 (20%) patients with serious infections including 45 (17.7%) bacterial, 9 (3.5%) viral and 5 (2%) IFI (1 pulmonary cryptococcosis, 4 pulmonary aspergillosis). Anti-mold prophylaxis was prescribed to 7 (2.8%) patients, none of whom developed IFI. Risk factors associated with serious infection included ECOG score ≥ 2 (OR 4.6, p < 0.001), concurrent steroid use (≥ 10 mg prednisone daily for ≥ 2 weeks; OR 3.0, p < 0.001), neutropenia (OR 3.6, p < 0.01), lymphopenia (OR 2.4, p < 0.05) and maximum ibrutinib dose of 560 mg (OR 2, p < 0.05). There was a dose dependent increase in infections based on number of chemotherapy regimens prior to ibrutinib initiation: 14.3% with 0, 19.7% with 1-2 and 28.7% with ≥ 3 prior treatments. Conclusion The incidence of serious infection in hematologic patients on ibrutinib was higher than previously reported (20% versus 11%) but the rate of IFI was lower (2% versus 4%). High ECOG score, leukopenia, steroids, and higher ibrutinib doses were associated with an increased risk for serious infection. Targeted antimicrobial prophylaxis should be considered for patients on ibrutinib with these risk factors. Improving functional status may also reduce the risk of infection in patients on ibrutinib. Disclosures All Authors: No reported disclosures

scholarly journals Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions

2021 ◽  
Vol 7 (2) ◽  
pp. 156
Author(s):  
Will Garner ◽  
Palash Samanta ◽  
Ghady Haidar
Keyword(s):  
Risk Factors ◽  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Fungal Infections ◽  
Antigen Receptor ◽  
Invasive Fungal Infections ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T

Studies describing invasive fungal infections (IFIs) after chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited. Although post-CAR-T-cell IFIs appear to be uncommon, they are associated with significant morbidity and mortality. Specific risk factors for IFIs in CAR-T-cell recipients have not been fully characterized and are often extrapolated from variables contributing to IFIs in patients with other hematologic malignancies or those undergoing hematopoietic cell transplant. Optimal prophylaxis strategies, including the use of yeast versus mold-active azoles, also remain ill-defined. Further research should investigate key risk factors for IFIs and establish an evidence-based approach to antifungal prophylaxis in these patients in order to improve clinical outcomes.

scholarly journals Invasive fungal infections in liver transplantation

2011 ◽  
Vol 15 (5) ◽  
pp. e298-e304 ◽  
Author(s):  
Xia Liu ◽  
Zongxin Ling ◽  
Lanjuan Li ◽  
Bing Ruan
Keyword(s):  
Liver Transplantation ◽  
Fungal Infections ◽  
Invasive Fungal Infections

scholarly journals Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

Blood ◽  
2018 ◽  
Vol 131 (17) ◽  
pp. 1955-1959 ◽  
Author(s):  
David Ghez ◽  
Anne Calleja ◽  
Caroline Protin ◽  
Marine Baron ◽  
Marie-Pierre Ledoux ◽  
...  
Keyword(s):  
Risk Factors ◽  
Invasive Aspergillosis ◽  
Early Onset ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Key Points

Key Points Ibrutinib may be associated with invasive fungal infections especially IA. Most infections usually occur during the first months of treatment, often in patients with other risk factors for fungal infections.

Sign in / Sign up

Export Citation Format

Share Document